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Summary
Background—Current manufacturing methods for recombinant human Factor VIII (rFVIII)
within mammalian cell cultures are inefficient which limit the abundance needed for affordable,
worldwide treatment of hemophilia A. However, rFVIII has been expressed at very high levels by
the transgenic mammary gland of mice, rabbits, sheep and pigs. Unfortunately, it is secreted into
milk with low specific activity due in part to the labile, heterodimeric structure that results from
furin processing of its B domain.
Objectives—To express biologically active rFVIII in the milk of transgenic mice through
targeted bioengineering.
Methods—Transgenic mice were made with a mammary specific FVIII gene (226/N6)
bioengineered for efficient expression and stability containing a B domain with no furin cleavage
sites. 226/N6 was expressed with and without von Willebrand Factor (VWF). 226/N6 was
evaluated by ELISA, SDS-PAGE, Western blot, and one- and two-stage clotting assays.
Hemostatic activity of immunoaffinity enriched 226/N6 was studied in vivo by infusion into
hemophilia A knockout mice.
Results and conclusions—With or without co-expression of VWF, 226/N6 was secreted into
milk as a biologically active single chain molecule that retained high specific activity similar to
therapeutic-grade FVIII. 226/N6 had >450-fold higher IU/ml than previously reported in cell
culture for rFVIII. 226/N6 exhibited similar binding to plasma-derived VWF as therapeutic-grade
rFVIII and intravenous infusion of transgenic 226/N6 corrected the bleeding phenotype of
hemophilia A mice. This provides proof-of-principle to study expression of 226/N6 and perhaps
other single chain bioengineered rFVIII in the milk of transgenic livestock.
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Introduction
Hemophilia A is an X-linked, inherited disorder of blood coagulation primarily caused by
deficiency or dysfunction of factor VIII (FVIII) that affects approximately one in every
5,000-10,000 males [1-3]. While occurring at only 100 to 200 ng/ml in blood plasma, FVIII
is a post-translationally complex, large glycoprotein of about 260 to 280 kDa [4-6]. FVIII
acts as an essential co-factor to Factor IX in the coagulation cascade to amplify the
activation of Factor X by >1000-fold. The structural complexity of FVIII [7] remains at the
core of therapeutic problems such as abundance and frequently encountered inhibitory
immune responses to intravenous therapy. Thus, both the development of universal
prophylactic and non-intravenous, low bioavailability treatments in economically developed
countries and routine access in developing countries are precluded [1,8,9].
The biosynthesis and secretion of FVIII into blood plasma by hepatocytes and recombinant
FVIII (rFVIII) by mammalian cells are greatly and similarly inefficient due to limitations in
transcription [10-12], post-translational processing and translocation from the endoplasmic
reticulum to the Golgi apparatus [13,14]. The most biosynthetically restricted rFVIII
structure is the analogue of native FVIII containing it's full length (907 amino acids,90 kDa)
B domain (FL-rFVIII). The B domain is processed by furin at two different sites leading to a
complex mixture of labile [15] metal ion stabilized, heterodimers (Fig. S1). Thus, all
therapeutic-grade plasma-derived FVIII (FL-FVIII) and FL-rFVIII are heterodimeric and
contain no single chain species [7]. von Willebrand Factor (VWF) helps stabilize the labile,
heterodimeric structure of both FL-FVIII in blood circulation and FL-rFVIII in cell culture
media. Although VWF does not increase the expression levels of FL-rFVIII protein, the
presence of VWF in cell culture media increases the accumulation of FVIII activity to about
1-2 IU/ml which is about the same as is in normal human plasma [16].
We and others have previously reported high concentrations of FL-rFVIII in the milk of
transgenic mice [17], rabbits [18,19], sheep [20] and pigs [21] showing that the mammary
gland can efficiently secrete rFVIII with a full B domain. However, the specific activity of
the FL-rFVIII was very low at about 0 to 10% of expected levels (Table S1). The native
appearance of the FL-rFVIII heavy and light chains found in these milks suggested that the
conformation of the assembled, heterodimer and not necessarily proteolytic degradation was
the main cause of the low activity in milk (Fig. S2) [21].
Unlike previous studies which expressed FL-rFVIII in milk, this study expresses a
bioengineered rFVIII with a modified B domain (226/N6) having no furin sites in the
presence and absence of the potentially stabilizing influence of recombinant VWF (rVWF)
co-expressed in mouse milk. The consensus sites for furin cleavage at Arg1313 and
Arg1648 were removed by truncating the B domain to the first 226 amino acids (Fig. S1B).
We provide the first report of rFVIII made at high levels in transgenic milk with native
procoagulant activity.
Materials and Methods
All animal procedures were approved by the Institutional Animal Care and Use Committee
at the University of Michigan and Virginia Polytechnic Institute and State University.
DNA constructs
The 226/N6 (WAP7FVIII-226/N6) construct was assembled by altering the Kpn I site of
pUCWAP6 [22] by introducing a Sal I site immediately downstream of the 4.1 kbp WAP
(whey acidic protein) promoter and ahead of the 1.7 kbp of mouse WAP 3’ UTR containing
the coding of the polyadenylation signal to produce pUCWAP7. The sequence for
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FVIII-226/N6 was removed by restriction enzyme digest using Sal I and Xho I from
pMT2226/N6 as described previously [14] and introduced into the Sal I site of pUCWAP7
yielding the pUCWAP7FVIII-226/N6 plasmid. The plasmid pUCWAP6VWF containing the
WAP6VWF expression construct (gift from Dr. Henryk Lubon, American Red Cross,
Rockville, MD) contained the cDNA for VWF placed between the 4.1 kbp WAP promoter
and the 1.7 kbp 3’UTR. The plasmid designated PPL456 containing the BLG (beta
lactoglobulin) driven AAT construct, which has been previously described [23], was a gift
from Dr. David Ayares (Revivicor, Blacksburg, Virginia). The WAP7FVIII-226/N6 was
released by Not I. The WAP6VWF was released by digestion with Not I and Sfi I. The
BLG-AAT was released by digestion with Not I and Sal I. All constructs were purified by
extraction prior to microinjection using a Nucleospin Extract kit (Clonetech Laboratories,
Inc. Palo Alto, CA).
Transgenic mouse generation, identification and milk collection
Transgenic mice were generated by pronuclear microinjection of purified DNA constructs as
previously described [24] at the Transgenic Core facility at the University of Michigan.
Southern analysis was performed as previously described [21]. PCR probes (KPL, Inc.
Gaithersburg, Maryland) are shown in Figure S3A. 500 bp PCR primers were: for WAP,
WAPprobeS1 (gcatgctcacactcaacagg)/ WAPprobeA1 (taagagtgtggaggcgcttg); for AAT,
same primers as for PCR, BLG-S1/AAT-A1. Milk was collected and defatted as previously
described [24]. Samples were stored at -70°C.
Factor VIII Biochemical Analysis
FVIII activity was measured by one-stage aPTT clotting assay on an MLA Electra 750
fibrinometer by reconstituting human FVIII-deficient plasma (George King Bio-Medical
Inc., Overland Park, Kansas) and modified two-stage assay utilizing the COAMATIC Factor
VIII (Chromogenix, Milano, Italy) according to the manufacturer's instructions. FVIII
antigen levels were determined by ELISA kit (Affinity Biologicals Inc., Ancaster, ON,
Canada) which assumed a FVIII concentration of 200 ng/mL per 1 IU/mL of activity (5000
IU/mg). 1 IU/ml is the defined concentration of Factor VIII activity in normal human plasma
which contains an average concentration of 100-200 ng per ml.
Immunoaffinity chromatography enrichment of 226/N6
Defatted milk was diluted and incubated overnight with anti-heavy chain FVIII monoclonal
antibody-conjugated sepharose beads (kindly provided by Baxter BioScience, Deerfield, IL).
The enrichment procedure was carried according to the protocol described previously [25]
with and without wash steps with 250 mM CaCl2 and MgCl2 to disrupt FVIII:VWF
complexes [26] prior to elution of FVIII. 1 mg/ml AAT was added as a stabilizer after IAC
enrichment. 226/N6 from CHO cells was enriched from stably-transfected CHO cell lines as
described previously [14].
Immunoblotting
Non-reduced and reduced samples were evaluated by sodium dodecyl sulfate
polyacrylamide (SDS-PAGE) gel electrophoresis on 4-12% NuPage® Bis-Tris gels
(Invitrogen Carlsbad, CA) and then electroblotted onto polyvinylidene fluoride (PVDF)
membranes (Millipore, Billerica, MA). Blots were probed with polyclonal antibodies for
FVIII (USBiological, F0016-10, Swampscott, MA), VWF (USBiological, V2700-04B,
Swampscott, MA) or AAT (USBiological, A2298-27H, Swampscott, MA).
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FVIII-VWF binding ELISA
226/N6 and rFVIII (Advate®, gift from Baxter) were incubated with 1% FVIII-deficient
human plasma (George King Bio-Medical). Triplicate samples were incubated with an anti-
FVIII antibody (BO2C11, gift from Marc Jacquemin, University of Leuven, Belgium) that
inhibits VWF binding[27] prior to incubation with 1% FVIII-deficient human plasma.
Samples were loaded into 96-well plates pre-coated with anti-FVIII antibody (F8C-EIAC,
Affinity Biologicals). Anti-VWF antibody (p0266, Dako, Carpenteria, CA) was used to
detect VWF binding. Absorbance was read at 490 nm.
In vivo tail clip assay in hemophilia A (HA) mice
Hemophilia A exon 16 knockout mice [28] were subjected to a tail clip bleeding assay. Mice
at least 10 weeks of age were injected with immunoaffinity enriched FVIII proteins. C57BL/
6 and HA mice littermates were used as controls for injection with lactated Ringer's (LR)
solution. Mice were injected with 80 IU/kg body weight of FVIII in 100 μl LR solution via
tail vein. Ketamine 85 mg/kg with xylazine 5 mg/kg was injected IP to induce anesthesia.
After 5 minutes, tails were cut at 1.5 mm diameter from tail tips then immediately
submerged into 14 ml conical tubes filled with saline at 37°C. Blood from the tail was
collected 10 minutes. Blood loss was quantified by the difference in tube weight at time 0
and 10 minutes. Mice were subsequently euthanized.
Statistical analysis
Data are presented as mean ± standard deviation except for bleeding data which was
presented as median ± standard deviation. A single factor analysis of variance (ANOVA)
was performed to compare blood loss results. Student's t-tests (two-tailed) assuming unequal
variances were used to compare each treatment group with control mice. An alpha level of
0.05 was used for all statistical analysis.
Results
Production and selection of transgenic mice by expression levels
We made monogenic and bigenic 226/N6 mice using three different transgenes (Fig. S3) to
help test the following hypotheses: 1) Single chain rFVIII would be expressed at a range of
concentrations in milk similar to or higher than that of FL-rFVIII; 2) Co-expressed rVWF
would complex 226/N6 and help stabilize single chain rFVIII made in milk as it does in
plasma and cell culture; and 3) Single chain rFVIII would have higher specific activity than
FL-rFVIII when expressed in milk. An optimized beta-lactoglobulin, Alpha1 Antitrypsin
gene (BLG-AAT) was used to make lineages of bigenic and trigenic 226/N6 mice in an
effort to mitigate transcriptional silencing which occurs in >60% of mammary expression in
transgenic mice. Silencing was decreased to about 25% in the presence of mice co-injected
with the BLG-AAT transgene [29,30]. Twenty different potential founder animal litters were
made by outbreeding with control animals. Transgenic mice maintained a natural lactation
length of about 17 days and had normal litter growth. About 50 to 100 μl of milk was
obtained per milking.
Detectable levels of rFVIII protein and activity occurred in some monogenic mice for 226/
N6 alone while no rFVIII protein or activity was detected in milk from mice bigenic for 226/
N6 and rVWF (Table 1). In the presence of the BLG-AAT milk gene, the frequency of both
226/N6 protein and activity levels was much higher for bigenic (226/N6 and BLG-AAT)
and trigenic (226/N6, rVWF and BLG-AAT) lineages than monogenic 226/N6 mice. For
these bigenic and trigenic mice containing the BLG-AAT gene, Alpha1-antitrypsin (AAT)
was expressed at >1 mg/ml (Fig. S4). In summary, while transgene silencing likely occurred
in some lineages, the concentration range of 226/N6 found in the milk of all mice was
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similar to previously reported concentration ranges for FL-rFVIII made in the milk of mice,
rabbits, sheep and pigs with the highest concentration of 226/N6 being about 0.2 to 0.3 mg/
ml.
Specific clotting activity and analysis by Western blot
We studied the transgenic mice with the highest 226/N6 expression levels and expanded
those lineages. The specific activity was determined directly in the whole milk pools by
measurement of FVIII antigen by ELISA and coagulation activity by aPTT assay (Table 1).
Notably, the 226/N6 specific activities found in the milks from monogenic, bigenic and
trigenic mice were all similar and typical of plasma-derived FVIII or FL-rFVIII.
Importantly, it was also functional without the presence of AAT or rVWF. Because there are
few high molecular weight proteins occurring in the milk of mice near or at the Mr of 226/
N6 or VWF under reducing conditions, quantitative Western blotting was possible. The high
226/N6 protein levels determined by ELISA were confirmed using quantitative Western
analysis under reducing conditions (Fig. S5).
Interactions of 226/N6 with rVWF and VWF
Strong interactions between VWF and FVIII result from conformations stabilized by
intramolecular disulfide bonding within FVIII and VWF subunits. The interactions between
FL-FVIII:VWF in therapeutic-grade preparations are not appreciably destabilized by
treatment with SDS under non-reduced conditions as evidenced by the decreased mobility
seen in Western blot analysis (Fig. 1). Reduced conditions destabilize these binding
interactions resulting in greater mobility that is commensurate with the molecular size of
FVIII and VWF monomers, respectively. In contrast, purified preparations of therapeutic-
grade FVIII containing no VWF do not show the greatly decreased electrophoretic mobility
in SDS-PAGE under non-reduced or reduced conditions. This intramolecular disulfide
bridge dependent phenomenon occurring within the VWF and FVIII molecules was used to
help determine the extent of 226/N6 complexation with rVWF in milk. The electrophoretic
migration of heterodimers under reduced and nonreduced conditions for therapeutic-grade
FL-rFVIII made in CHO cells not containing VWF was similar. The Mr of the heterodimers
was consistent with the published range of 100-220 kDa (Fig. 1A and 1B, respectively)
while possessing no signal for VWF (Fig.1C and 1D, respectively).
A trigenic (226/N6, rVWF and BLG-AAT) mouse milk pool containing 300 μg/ml of both
226/N6 and rVWF, showed a single predominant FVIII signal at about 190 kDa under
reduced conditions. The VWF signal had a similar Mr (about 320 kDa) to the plasma
derived FVIII:VWF reference under reduced conditions. Importantly, the same shift to a
retarded migration of Mr >420 kDa occurred for the trigenic sample under nonreduced
condition as occurred with the plasma-derived FVIII:VWF complex. Bigenic mouse milk
containing no rVWF migrated similarly to the trigenic sample under reduced conditions, but
did not exhibit the greatly retarded migration under nonreduced conditions. These results
show that 226/N6 was secreted as a single chain into milk with or without VWF.
Immunoaffinity chromatography (IAC) was applied to a whey phase made from
centrifugally clarified and diluted, trigenic mouse milk to provide an infusable preparation
enriched in 226/N6. The IAC captures FVIII and FVIII:VWF complexes. Trigenic milk was
treated with IAC with loading and wash conditions at which VWF:FVIII complexes were
unstable allowing most of the VWF to be efficiently released before and during
immunosorption of 226/N6. While the starting milk contained a 1:1 ratio of rVWF to 226/
N6, immunoaffinity enrichment reduced the stoichiometric ratio of rVWF to 226/N6 in the
FVIII eluate to about 0.1. The yield of 226/N6 from trigenic milk containing high levels of
226/N6 was 10% with an enrichment of 70-fold, and a purity of 39% before addition of
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AAT for storage. This IAC preparation was similar to an IAC enriched therapeutic-grade
FL-rFVIII made from Recombinate (Table 2). Importantly, the specific activity of the
immunoaffinity enriched 226/N6 from trigenic milk was similar to the original milk and also
the FL-FVIII and FL-rFVIII references (Table S2).
IAC was also applied to milk from low expressing animals that did not co-express VWF.
While the purity was <1% (Fig. S6), a enrichment of 16-fold was achieved for 226/N6 at a
similar specific activity to that found in the original milk (Table 2). The yield of 226/N6
captured from milk containing 226/N6:VWF complexes was lower than the yields from non-
VWF expressing milk.
Using ELISA, we studied the complexation of human plasma-derived VWF with 226/N6
that could occur in FVIII-deficient plasma derived from a severe hemophilic A donor. We
used this model to determine if 226/N6:VWF complexes would form in a context more
pertinent to future hemophilia A treatment. The IAC enriched 226/N6 preparations and
therapeutic-grade FL-rFVIII were immunocaptured on a microtiter plate. The immobilized
anti-FVIII monoclonal antibody has been shown to not interfere with VWF binding. The
presence of VWF bound to the immunocaptured 226/N6 was detected by anti-VWF
polyclonal antibody. To determine the specificity of the interaction between 226/N6 and
VWF in blood plasma, we pre-incubated each immunocaptured rFVIII species with and
without a monoclonal antibody (B02C11) that binds to the light chain of FVIII inhibiting
FVIII:VWF complexation [27]. In all cases, the B02C11 inhibited the VWF signal arising
from incubation in plasma to low background levels. Without pretreatment with B02C11,
both immunocaptured FL-rFVIII and 226/N6 exhibited strong VWF binding signals in a
similar dose-dependent fashion (Fig. 3). The similar polynomial fits to each of these
absorption profiles indicated that FL-rFVIII and 226/N6 have similar avidities for VWF in
human plasma.
Hemostatic potential of infused IAC enriched 226/N6
We studied the hemostatic efficacy of 226/N6 in vivo using a terminal tail transection
bleeding model in hemophilia A mice. Figure 4 shows the median total blood loss observed
for normal C57/BL mice and FVIII knockout hemophilia A (HA) mice resulting from a
terminal tail transection. The HA mice were infused with lactated Ringer's (LR),
immunoaffinity enriched 226/N6 made in CHO cells or immunoaffinity enriched 226/N6
from milk. 226/N6 from CHO cells and 226/N6 from transgenic milk were each infused at
80 IU/kg body weight. Normal C57/BL mice showed a cessation of bleeding (4 of 4) at
about 2 to 5 minutes with a total weight of blood loss over 10 minutes ranging from 80 to
165 mg. HA mice infused with LR typically did not show a cessation of bleeding (10 of 12)
with total weight of blood loss ranging from 115 to 725 mg. HA mice infused with 226/N6
from CHO cells showed a cessation of bleeding (5 of 5) at about 2 to 5 minutes with a total
weight of blood loss ranging from 60 to 230 mg. HA mice infused with 226/N6 from
transgenic milk showed a cessation of bleeding (5 of 6) typically at about 2 to 5 minutes
with most mice having a total weight of blood loss ranging from 10 to 175 mg. Post hoc
analysis (two-tailed t-tests) determined that LR-treated hemophilia A mice bled significantly
more than LR-treated C57/BL mice (p = <0.001, α = 0.05), whereas both 226/N6 from CHO
cells and 226/N6 from transgenic milk treated HA mice had similar blood losses as LR-
treated C57/BL mice (p = 0.574 and 0.491, respectively, α = 0.05).
Discussion
Production of rFVIII in the milk of transgenic livestock is a promising approach to making
rFVIII therapy significantly more abundant. Producing a greater abundance of rFVIII will
help advance immunotolerance and non-intravenous therapy [31,32]. Towards that goal, our
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previous work showed that FL-rFVIII was efficiently secreted into milk at 10 to 1000-fold
higher concentrations than is seen in blood plasma or cell culture (Table S1). However, the
specific activity of the FL-rFVIII was very low. The broad range of FL-rFVIII levels
expressed in milk is likely caused by transcriptional inefficiency that often occurs as a result
of transgene integration into less transcriptionally active chromosomal sites [29,30]. In
founder lineages with favorable integration sites for expression, this work shows that 226/
N6 can be made at high concentrations similar to that of FL-rFVIII. Therefore, 226/N6 is at
least as efficiently secreted by the mammary gland as FL-rFVIII where additional
improvements in transcriptional efficiency might enable even higher levels. The 226/N6,
which has a modified B domain lacking furin sites, yielded a specific activity similar to
therapeutic-grade reference FL-FVIII and FL-rFVIII. Importantly, the infusion of IAC
enriched 226/N6 from milk or CHO cells corrected the hemostatic defect of FVIII knockout
mice in response to a tail transection trauma challenge.
Co-expressed AAT did not appear to impact the specific activity of the milk-borne 226/N6
since the specific activities of 226/N6 produced by monogenic, bigenic and trigenic mice
were similar. AAT was added to enriched preparations to inhibit plasmin generation during
storage because plasmin is a naturally occurring, broadly acting protease in milk [33,34].
The general co-expression of milk protease inhibitors in order to protect the recombinant
protein product is still a future developmental goal.
This is the first report of any rFVIII co-expressed in milk with rVWF. FVIII circulates as a
complex with VWF which is a prerequisite for its stability and thus survival in circulation
[13,35]. Therapeutic-grade FL-FVIII:VWF complex and 226/N6 in the presence of co-
expressed rVWF had similarly reduced electrophoretic mobility. This, in addition to the
similar in vitro binding of plasma-derived VWF by 226/N6, suggests that co-expressed
VWF:226/N6 complexes existed in the milk. The native binding behavior of 226/N6 with
plasma-derived VWF indirectly shows that the proper post-translational sulfation of tyrosine
1680 in the A3 domain of 226/N6 likely occurred as it is required for complexation [36].
226/N6 expressed with and without rVWF in milk had >450-fold higher activity levels than
the analogous bioreactor production of FL-rFVIII and >40-fold higher than expression of
226/N6 in CHO cell culture without rVWF [14]. The high activity levels accumulating in the
milk in the presence or absence of rVWF is likely a reflection of the inherent stability of
226/N6. This contrasts the beneficial effects of co-expressed VWF in cell culture which
stabilizes FL-rFVIII and increases its accumulated activity levels [13,15,16]. The result of
this study has been our first proof that VWF would bind to this 226/N6 design and that a co-
expressed FVIII:VWF product may be feasible in milk.
We acknowledge that utilization of a bioengineered rFVIII could result in neoantigenicity;
however, the advantage of the 226/N6 design is that its bioengineering strategy targets
modifications to the B domain where inhibitor antibodies have infrequently been described.
In addition, after thrombin activation, 226/N6 assumes a active FVIII structure that is
identical to full-length wild type FVIII [14]. There is also evidence that VWF complexation
with FVIII increases the effectiveness of immune tolerance therapy [37]. Thus, the ability of
226/N6 to complex with co-expressed rVWF and plasma-derived VWF may be a beneficial
attribute in the development of future applications of transgenically produced rFVIII.
The safety and efficacy of transgenic milk-derived products has crossed an important
threshold as the US FDA and EMEA have approved recombinant anti-thrombin III made in
goat milk (ATRYN®) [38]. Our study in mice provides the fundamental understanding
needed for the future expression of biologically active, single chain rFVIII molecules of
different designs in the milk of livestock. Pigs are a likely choice of transgenic livestock for
future production of rFVIII [32] because they combine the advantages of milk volume and
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hepatocyte-like post-translational biochemistry such as glycosylation [39]. With respect to
226/N6, which retains six of the 19 potential glycosylation sites in the B domain, the
glycosylation may impact pharmacokinetics. While ruminants also provide ample milk
volume, their mammary biochemistry produces higher mannose, low sialic acid glycoforms
which may affect circulation residence times due to interactions with asialyo receptors found
in the human liver [40]. Given the fundamental knowledge about rFVIII stability provided
by our studies in mice and pigs, we have begun to make transgenic pigs with various
modified B domain FVIII constructions. In contrast with mice, the amount of rFVIII that
will be produced in pig milk will permit bioengineering studies on purification and
formulation. The advantage of pig milk over other FVIII sources such as cell culture
bioreactors and human plasma is evident in the greater than two orders of magnitude
reduction in source volume estimated to meet global FVIII demand [38] (Table S3).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
SDS-PAGE of FL-rFVIII and milk-borne 226/N6 in the presence and absence of VWF
under reduced and non-reduced conditions. Assessment of VWF binding by (A) reduced
anti-FVIII, (B) non-reduced anti-FVIII, (C) reduced anti-VWF, and (D) non-reduced anti-
VWF SDS-PAGE Western Blots. All blots contain a molecular weight marker (MW),
recombinant FVIII (FL-rFVIII), plasma-derived FVIII:VWF concentrate (FVIII:VWF),
diluted trigenic mouse milk equivalent to 0.07 μl undiluted milk (226/N6:rVWF:AAT
Milk), diluted non-transgenic mouse milk equivalent to 0.07 μl undiluted milk (Control
Milk) and diluted bigenic mouse milk equivalent to 0.07 μl undiluted milk (226/N6:AAT
Milk). Arrows indicate primary single chain 226/N6 species.
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Fig. 2.
SDS-PAGE of IAC enriched 226/N6. 226/N6 and rVWF were immunoaffinity enriched
from transgenic mouse milk and separated during the enrichment process. Enrichment of the
226/N6 and rVWF was performed on clarified, diluted milk pooled from six F3 trigenic
mice from the 415-101-2 line and analyzed by reduced SDS PAGE (A) and anti-FVIII (B)
and anti-VWF (C) Western blots. The SDS-PAGE gel contains a molecular weight marker
(MW), a FVIII reference (FL-rFVIII; Recombinate), a VWF reference (VWF), diluted non-
transgenic mouse milk equivalent to 0.07 μl undiluted milk (Control Milk), diluted trigenic
mouse milk equivalent to 0.07 μl undiluted milk (226/N6:rVWF Milk), and trigenic milk
product enriched by immunoaffinity chromatography (IAC Eluate). The enriched 226/N6 is
shown by the closed arrow ( ). The open arrow ( ) points to the AAT that was added at 1
mg/ml to the IAC eluate for storage formulation. Each blot contains a molecular weight
marker (MW), a reference (FL-rFVIII and/or VWF), trigenic transgenic mouse milk (226/
N6:rVWF Milk), and immunoaffinity enriched trigenic milk product (IAC Eluate).
Pipe et al. Page 12
J Thromb Haemost. Author manuscript; available in PMC 2012 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 3.
Plasma VWF binding of IAC enriched 226/N6. The relative affinity of VWF for 226/N6
immunoaffinity enriched from milk from trigenic mice (◆) and FL-rFVIII ( ) were
compared by ELISA. The specificity of VWF binding was also evaluated by preincubating
226/N6 immunoaffinity enriched from milk from trigenic mice (◇) and FL-rFVIII ( ) with
a monoclonal antibody (BO2C11) which binds to FVIII and inhibits VWF binding.
Polynomial trendlines are shown for the reference FL-rFVIII (gray line) and 226/N6 (black
line) in the absence of the inhibitor and the reference FL-rFVIII (dotted gray line) and 226/
N6 (dotted black line) in the presence of the inhibitor. Error bars represent standard
deviation.
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Fig. 4.
Hemostatic efficacy in vivo of 226/N6 within the hemophilia A mouse model. Total blood
loss (in mg) over 10 min was observed for normal C57/BL mice and FVIII knockout
hemophilia A (HA) mice resulting from a terminal tail transection. The HA mice were
infused with either lactated Ringer's (LR), immunoaffinity enriched 226/N6 from CHO cells
or immunoaffinity enriched 226/N6 from transgenic milk. An analysis of variance indicated
that the effect of treatment was significant (p < 0.001). Post hoc analysis determined that on
LR-treated hemophilic A mice bled significantly more than LR-treated control mice (p =
<0.001). An α of 0.05 was used as a significance criterion for all statistics. Bars represent
the median blood loss and the error bars the standard deviation.
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Table 1
The specific activity of 226/N6 in milk.
Mouse Genotype
Mouse ID
226/N6 Concentration (μg/ml) aPTT Activity Level (IU/ml) Specific Activity (IU/mg)
Monogenic mice: 226/N6
    1960-1702 0.144 0.6 4,167
    1926-1742 0.093 0.1 1,075
    46-1247 0.066 0.4 6,061
Bigenic mice: 226/N6-rVWF
    376-8 Not Detected Not Detected
    376-12 Not Detected Not Detected
    383-49 Not Detected Not Detected
Bigenic mice: 226/N6-BLG-AAT
    875-234 34 25 735
    875-233 6.2 44 7,097
    516-46 7.3 13 1,781
    406-128-10 83 122 1,470
Trigenic mice: 226/N6-rVWF-BLG-AAT
    415-101-2 183 678 3,705
    415-101-1-2 122 555 4,549
1 IU/ml is the defined concentration of FVIII activity in normal human plasma. An average concentration of 200 nanograms per ml normal human
plasma is assumed yielding a theoretical specific activity of 5,000 IU/mg.
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